SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

31 Jul 2026 Evaluate
The company witnessed a 23.18% growth in the revenue at Rs. 14886.70 millions for the quarter ended June 2026 as compared to Rs. 12085.60 millions during the year-ago period.A slim rise of 23.73% was recorded in the Net profit for the quarter ended June 2026 to Rs. 3154.70  millions  From Rs. 2549.70 millions.The company reported a good operating profit of 4675.20 millions compared to 3700.30 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 14886.70 12085.60 23.18 14886.70 12085.60 23.18 48459.20 43220.40 12.12
Other Income 708.20 406.30 74.30 708.20 406.30 74.30 2044.00 1198.70 70.52
PBIDT 4675.20 3700.30 26.35 4675.20 3700.30 26.35 14023.90 13245.90 5.87
Interest 7.60 7.30 4.11 7.60 7.30 4.11 25.90 46.00 -43.70
PBDT 4667.60 3693.00 26.39 4667.60 3693.00 26.39 13998.00 13199.90 6.05
Depreciation 433.10 403.10 7.44 433.10 403.10 7.44 1687.70 1399.30 20.61
PBT 4234.50 3289.90 28.71 4234.50 3289.90 28.71 12310.30 11800.60 4.32
TAX 1079.80 740.20 45.88 1079.80 740.20 45.88 2842.10 2631.70 7.99
Deferred Tax 63.50 32.90 93.01 63.50 32.90 93.01 76.00 51.40 47.86
PAT 3154.70 2549.70 23.73 3154.70 2549.70 23.73 9468.20 9168.90 3.26
Equity 250.70 250.70 0.00 250.70 250.70 0.00 250.70 250.70 0.00
PBIDTM(%) 31.41 30.62 2.57 31.41 30.62 2.57 28.94 30.65 -5.57

Ajanta Pharma Share Price

3484.40 12.40 (0.36%)
07-Aug-2026 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1940.00
Dr. Reddys Labs. 1166.65
Cipla 1465.70
Lupin 2356.00
Zydus Lifesciences 1108.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: